“We are hoping to use this competition not just as a way to examine the capacity of people to predict vaccination outcomes, but also as a way to address an important public health question,” says Peters.
Cancer researcher Miguel Reina-Campos, Ph.D., has joined the faculty of La Jolla Institute for Immunology (LJI) as an Assistant Professor to lead the Laboratory of Tissue Immune Networks. His laboratory at LJI aims to investigate the basis of CD8+ T cell tissue immunity to improve life-saving cancer immunotherapies.
Scientists at La Jolla Institute for Immunology (LJI) have uncovered important clues to how human T cells combat the bacterium that causes tuberculosis.
“We found sort of a special ‘flavor’ of CD4+ T cells critical for clearing this chronic virus replication,”
"These patients may be candidates in whom immunotherapy has the potential to show clinical benefit."
According to new predictions by La Jolla Institute for Immunology (LJI) researchers, if the new SARS-CoV-2 Pirola variant wants to evade T cells, it isn't doing a very good job.
In a new Cell study, scientists at La Jolla Institute for Immunology (LJI) and Massachusetts General Hospital, Harvard Medical School, show how a protein called IKAROS helps "weave" the genome.
Clarivate calls these scientists "pioneers," noting that ranking on the Highly Cited Researchers list is a sign that a scientist has published significant findings and influenced their field of study.
The award recognizes Saphire's leadership and innovative research toward addressing the urgent need for effective antibody therapeutics against COVID-19 and viral threats such as Ebola and Lassa virus.
LA JOLLA, CA—Scientists from La Jolla Institute for Immunology (LJI) and The University of Southampton, UK, have uncovered a group of immune cells that may drive severe asthma. These cells, called cytotoxic CD4+ tissue-resident memory T cells, gather in the lungs and appear to possess the molecular weaponry to cause the most harm in men who developed asthma later in life.
La Jolla Institute for Immunology (LJI) scientists have published a pair of studies that show how we might harness CD4+ T cells while boosting the cancer-fighting power of CD8+ "killer" T cells.
According to new research in the journal Immunity, T cells have a nuclear receptor doing something very odd—but very important—to help them fight pathogens and destroy cancer cells.
The study, led by scientists at La Jolla Institute for Immunology (LJI), reveals the inner workings of viral factories, clusters of viral proteins and genomes that form in host cells.
Support for early career researchers is about to get a major boost, thanks to a new fellowship fund established by leaders at La Jolla Institute for Immunology (LJI) and Japan-based global pharmaceutical corporation, Kyowa Kirin, Inc.
In a new study, scientists at La Jolla Institute for Immunology (LJI) compared the immune response of individuals who received older versus newer versions of the whooping cough vaccine. The unexpected findings may help explain the recent rise in whooping cough cases and point to potential targets for the next generation of vaccines.
Immune system researchers have designed a computational tool to boost pandemic preparedness. Scientists can use this new algorithm to compare data from vastly different experiments and better predict how individuals may respond to disease.
Scientists at La Jolla Institute for Immunology show that T cells can recognize several different viral targets, called "antigens," shared between most coronaviruses, including common cold coronaviruses and SARS-CoV-2. They also looked more in-depth at what fragments of these antigens, called “epitopes,” are recognized and how conserved they are across different coronaviruses.
La Jolla Institute for Immunology (LJI) is pleased to welcome biophysicist and immune system researcher Tal Einav, Ph.D., to the Institute’s faculty. His laboratory at LJI will develop new tools in computational biology and shed light on how human antibodies neutralize deadly viruses.
A San Diego team, led by scientists at La Jolla Institute for Immunology (LJI), has won the top prizes in the Nucleate Activator competition. Out of 1,000 initial competitors, the LJI team advanced to the final four teams and swept all the prizes they entered for. Their winning research proposal outlines how scientists could stop dengue virus and Zika virus by developing sophisticated vaccines that activate both B cells and T cells.
In a new study, published in Nature Cell Biology, scientists at La Jolla Institute for Immunology (LJI) explored the location, function, gene expression, and metabolism of MAIT cells in the mouse lung.
In a new investigation, scientists from La Jolla Institute for Immunology (LJI) have shown how antibodies, collected from a clinical study volunteer, bind to the SARS-CoV-2 Spike protein to neutralize the virus.
La Jolla Institute for Immunology (LJI) Instructor Estefania Quesada Masachs, M.D., Ph.D., has won the 2023 Young Investigator of the Year Award from the Network for Pancreatic Organ donors with Diabetes (nPOD). This prestigious award recognizes Quesada Masachs' groundbreaking research in type 1 diabetes.
There are no vaccines or therapies available for lymphocytic choriomeningitis virus (LCMV) infection. This pathogen spreads easily and is extremely common in people worldwide.
A new grant of over $17 million from the National Institute of Allergy and Infectious Diseases (NIAID) has established La Jolla Institute for Immunology (LJI) as the leading institute for human immunology data curation, analysis, and dissemination. With this funding, LJI has taken the helm of the Human Immunology Project Consortium Data Coordinating Center, a critical tool in the effort to fuel scientific collaboration in immunoprofiling and highlight findings from the overall Human Immunology Project Consortium (HIPC).
Inmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks. Now scientists are looking at how we might harness their power in new antibody therapeutics and even more effective COVID-19 vaccines.
LA JOLLA, CA — Researchers at La Jolla Institute for Immunology (LJI) have at last uncovered how an enzyme called O-GlcNAc transferase (OGT) keeps cells healthy. Their findings, published in the Proceedings of the National Academies of Sciences, reveals a key aspect of cellular biology and may lead to important medical advances.
LJI Instructor Annie Elong Ngono, Ph.D., has spearheaded important studies into the immune response to deadly pathogens such as dengue virus. Now, this dedication to global health and virology has earned her acceptance to the Global Virus Network's (GVN) highly selective Rising Star Mentorship Program.
"This is a very striking and significant result that essentially separates LIGHT from any of the other inflammatory cytokines that have been implicated in the process in severe asthmatics."
"Vaccines such as JYNNEOS should be able to induce T cells that also recognize mpox and can provide protection from severe disease."
The 2022 "Highly Cited Researchers" list from Clarivate includes several La Jolla Institute for Immunology (LJI) scientists well versed in lay friendly communication. These experts are ready to share exciting new research with media and podcast outlets. Contact [email protected] to set up an interview and make arrangements for high quality audio capture.
Seven researchers at La Jolla Institute for Immunology (LJI) have been named to the 2022 Highly Cited List, released today by Clarivate.
La Jolla Institute for Immunology (LJI) researchers have made a major breakthrough in understanding how deletion of the genes that encode TET proteins can lead to cancer growth.
Cecilia Lindestam Arlehamn, Ph.D., aims to shed light on how sex-based immune system differences may affect the development and progression of these neurodegenerative diseases in men versus women.
The LJI team plans to use their new map of the Lassa virus surface glycoprotein to design a much-needed vaccine.
Scientists at La Jolla Institute for Immunology have uncovered an immune cell defect tied to the risk of developing MAC disease (a relative of tuberculosis).
LJI research shows that a "slow delivery, escalating dose" vaccination strategy can prompt B cells to spend months mutating and evolving their pathogen-fighting antibodies.
“We are delighted that Dick Bodman is rejoining our Board of Directors and to welcome Fred Miller to LJI as our newest board member."
Scientists solve mystery of how Zika virus targets key immune cell. New finding shed light on how to stop virus from spreading.
Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology (LJI), a globally recognized non-profit research organization dedicated to understanding the power of the immune system to promote human health, announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.
Cells in the gut send secret messages to the immune system. Thanks to new research from La Jolla Institute for Immunology (LJI) scientists, we can finally get a look at what they're saying.
For a glimpse into the future of SARS-CoV-2 immunity, scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system builds its defenses against common cold coronaviruses (CCCs).
Paramyxoviruses have the potential to trigger a devastating pandemic. This family of viruses includes measles, Nipah virus, mumps, Newcastle disease and canine distemper. An international team of collaborators has published the first-ever look at a key stage in the life cycles of measles and Nipah viruses. It reveals how future therapies might stop these viruses in their tracks.
In a new study, researchers show how a critical Lassa virus protein, called polymerase, drives infection by harnessing a cellular protein in human hosts. Their work suggests future therapies could target this interaction to treat patients.
Rabies virus kills a shocking 59,000 people each year, many of them children. In a new study, researchers from La Jolla Institute for Immunology and Institut Pasteur share a promising path to better vaccine design.
"Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
Detecting these T cells may lead to diagnostics to better detect heart disease—and disease severity.
To treat and prevent these diseases, researchers need to understand why a lack of oxygen would affect the immune system.
When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
Researchers at La Jolla Institute for Immunology (LJI) have found that Zika virus can mutate to become more infective—and potentially break through pre-existing immunity.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
